相关实验视频

Updated: Sep 14, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

在小鼠模型中,empagliflozin不能阻止Dent型1型疾病的进展

Elise de Combiens^1,2, Nadia Frachon^1,2, Yohan Bignon³

¹Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris, France.

Experimental physiology

|July 22, 2025

概括

恩帕格利弗洛辛在丹特病小鼠模型中降低了损伤标志物. 然而,这种-葡萄糖共运输体2 (SGLT2) 抑制剂并没有阻止疾病的进展或功能下降.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

丹特病是一种罕见的遗传性脏疾病,导致近端管管功能障碍和慢性脏疾病的进展.
没有针对性的治疗方法;目前的治疗方法可以控制症状并减缓疾病的进展.
一个模仿丹特病1型的小鼠模型被开发用于研究疾病机制.

研究的目的:

调查Empagliflozin在Dent病中的潜在脏保护作用.
为了评估empagliflozin对管管损伤,蛋白尿,高尿,炎症,纤维化和膜过率下降的影响.

主要方法:

给出empagliflozin (一种-葡萄糖携带载体2抑制剂) 的Dent病型1敲入小鼠.
评估脏和尿液中的Lipocalin-2 (LCN2) 水平作为管道损伤的标志物.
评估蛋白尿,高尿,炎,纤维化和膜过率.

主要成果:

恩帕格利弗洛辛显著降低了和尿液中的Lipocalin-2 (LCN2) 水平.
治疗并没有缓解低分子量蛋白尿或高尿.
恩帕格利弗洛辛并没有预防脏炎症,纤维化或膜过率的下降.

结论:

在Dent病小鼠模型中,empagliflozin证明了管道损伤标志物 (LCN2) 的降低.
尽管减少了LCN2,但empagliflozin未能阻止Dent型1型疾病向慢性脏疾病的整体进展.
这些发现表明,SGLT2抑制可能不是阻止Dent疾病进展的可行治疗策略.

关键词:

这是Dent的疾病.这是一种SGLT2抑制剂.艾姆帕格利夫洛辛 (Empagliflozin) 是一种靠近的管道靠近的管道

更多相关视频

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

Inducing Apical Periodontitis in Mice

Inducing Apical Periodontitis in Mice

Published on: August 6, 2019

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...